Key statistics
On Wednesday, Savara Inc (SVRA:NSQ) closed at 5.35, -23.63% below its 52-week high of 7.01, set on Dec 12, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 5.28 |
|---|---|
| High | 5.43 |
| Low | 5.10 |
| Bid | 5.00 |
| Offer | 5.37 |
| Previous close | 5.27 |
| Average volume | 1.41m |
|---|---|
| Shares outstanding | 203.47m |
| Free float | 198.86m |
| P/E (TTM) | -- |
| Market cap | 1.09bn USD |
| EPS (TTM) | -0.535 USD |
Data delayed at least 15 minutes, as of Feb 11 2026 21:00 GMT.
More ▼
- Savara Announces Participation in Upcoming Investor Healthcare Conferences
- Savara Announces Amendment to Hercules Capital Debt Facility Providing up to $75M of Additional Debt Funding Upon U.S. Food and Drug Administration (FDA) Approval of MOLBREEVI*
- Savara Announces New Employment Inducement Grant
- PANTHERx® Rare Selected by Savara as the U.S. Exclusive Specialty Pharmacy for MOLBREEVI*
- Savara Resubmits the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
- Savara Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference
- Savara Announces European Patent Office (EPO) Intends to Grant a Patent for the Liquid Formulation of MOLBREEVI*
- Savara and PARI Granted a European Patent Covering the Drug-Device Combination of MOLBREEVI* Delivered Via the Proprietary eFlow® Nebulizer System
- Savara Announces Participation in Upcoming Investor Healthcare Conferences
More ▼
